Peculiarities of the course of COVID-19 in patients with chronic noncommunicable diseases (literature review)

Abstract

An electronic search for publications on the features of the course of COVID-19 in patients with the most common chronic noncommunicable diseases (arterial hypertension, diabetes mellitus and obesity) was carried out using the Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, CyberLeninka databases, RSCI, as well as journals peer-reviewed by the Higher Attestation Commission. The review analyzed the effect of comorbidity on the prognosis of a new coronavirus infection (complication rate, severity of the course, mortality). It has been shown that previous noncommunicable diseases are a significant risk factor for adverse outcomes in patients with COVID-19, and if the effect of arterial hypertension is not confirmed by all authors, then type 2 diabetes mellitus, as well as any degree of obesity, are important prognostic signs of an unfavorable course of the new coronavirus infections.

Thus, in the context of the COVID-19 pandemic, patients suffering from chronic noncommunicable diseases need more careful monitoring and preventive measures aimed not only at preventing infection with the new coronavirus, but also at slowing the progression of these pathologies and their complications.

Keywords

review / COVID-19 / arterial hypertension / diabetes mellitus / obesity

References

[1] Zolnikova OYu, Svistunov AA, Ivashkin VT. SARS-COV-2: Immune response, structural changes, treatment strategies. Human Ecology. 2021;28(1):4–10. doi: 10.33396/1728-0869-2021-1-4-10

[2] Зольникова О.Ю., Свистунов А.А., Ивашкин В.Т. SARS-CoV-2: иммунный ответ, структурные изменения, основные терапевтические стратегии // Экология человека. 2021. Т. 28, № 1. C. 4–10. doi: 10.33396/1728-0869-2021-1-4-10

[3] Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–1839. doi: 10.1016/j.jiph.2020.07.014

[4] Ejaz H., Alsrhani A., Zafar A., et al. COVID-19 and comorbidities: Deleterious impact on infected patients // J Infect Public Health. 2020. Vol. 13, N 12. P. 1833–1839. doi: 10.1016/j.jiph.2020.07.014

[5] Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage — A review. Life Sci. 2020;255:117839. doi: 10.1016/j.lfs.2020.117839

[6] Renu K., Prasanna P.L., Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage — A review // Life Sci. 2020. Vol. 255. P. 117839. doi: 10.1016/j.lfs.2020.117839

[7] Kostinov MP, Shmitko AD, Polishchuk VB, Khromova EA. Modern representations of the new coronavirus and the disease caused by SARS-COV-2. Infectious Diseases: News, Opinions, Training. 2020;9(2):33–42. (In Russ). doi: 10.33029/2305-3496-2020-9-2-33-42

[8] Костинов М.П., Шмитько А.Д., Полищук В.Б., Хромова Е.А. Современные представления о новом коронавирусе и заболевании, вызванном SARS-CоV-2 // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 2. С. 33–42. doi: 10.33029/2305-3496-2020-9-2-33-42

[9] Jeong IK, Yoon KH, Lee MK. Diabetes and COVID-19: Global and regional perspectives. Diabetes Res Clin Pract. 2020;166:108303. doi: 10.1016/j.diabres.2020.108303

[10] Jeong I.K., Yoon K.H., Lee M.K. Diabetes and COVID-19: Global and regional perspectives // Diabetes Res Clin Pract. 2020. Vol. 166. P. 108303. doi: 10.1016/j.diabres.2020.108303

[11] Gromova OA, Torshin IYu. The importance of zinc in maintaining the activity of antiviral innate immunity proteins: Analysis of publications on COVID-19. Profilakticheskaya Meditsina. 2020;23(3):131–139. (In Russ). doi: 10.17116/profmed202023031131

[12] Громова О.А., Торшин И.Ю. Важность цинка для поддержания активности белков врождённого противовирусного иммунитета: анализ публикаций, посвящённых COVID-19 // Профилактическая медицина. 2020. Т. 23, № 3. С. 131–139. doi: 10.17116/profmed202023031131

[13] Mitkovskaya N, Grigorenko E, Ruzanov D, Statkevich T. Coronavirus infection COVID-19 and comorbidity. Science and Innovations. 2020;(7):50–60. (In Russ). doi: 10.29235/1818-9857-2020-7-50-60

[14] Митьковская Н., Григоренко Е., Рузанов Д., Статкевич Т. Коронавирусная инфекция COVID-19 и коморбидность // Наука и инновации. 2020. № 7. С. 50–60. doi: 10.29235/1818-9857-2020-7-50-60

[15] Joachimiak MP. Zinc against COVID-19? Symptom surveillance and deficiency risk groups. PLoS Negl Trop Dis. 2021;15(1):e0008895. doi: 10.1371/journal.pntd.0008895

[16] Joachimiak M.P. Zinc against COVID-19? Symptom surveillance and deficiency risk groups // PLoS Negl Trop Dis. 2021. Vol. 15, N 1. P. e0008895. doi: 10.1371/journal.pntd.0008895

[17] Barone MTU, Ngongo B, Harnik SB, et al. COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis. Diabetes Res Clin Pract. 2021;171:108587. doi: 10.1016/j.diabres.2020.108587

[18] Barone M.T.U., Ngongo B., Harnik S.B., et al. COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis // Diabetes Res Clin Pract. 2021. Vol. 171. P. 108587. doi: 10.1016/j.diabres.2020.108587

[19] Cheng S, Zhao Y, Wang F, et al. Comorbidities’ potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(12):e24971. doi: 10.1097/MD.0000000000024971

[20] Cheng S., Zhao Y., Wang F., et al. Comorbidities’ potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis // Medicine (Baltimore). 2021. Vol. 100, N 12. P. e24971. doi: 10.1097/MD.0000000000024971

[21] Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–628. doi: 10.1111/j.1464-5491.2006.01861.x

[22] Yang J.K., Feng Y., Yuan M.Y., et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS // Diabet Med. 2006. Vol. 23, N 6. P. 623–628. doi: 10.1111/j.1464-5491.2006.01861.x

[23] Bloomgarden ZT. Diabetes and COVID-19. J Diabetes. 2020;12(4):347–348. doi: 10.1111/1753-0407.13027

[24] Bloomgarden Z.T. Diabetes and COVID-19 // J Diabetes. 2020. Vol. 12, N 4. P. 347–348. doi: 10.1111/1753-0407.13027

[25] Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618–625. doi: 10.1111/j.1365-2362.2009.02153.x

[26] Oudit G.Y., Kassiri Z., Jiang C., et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS // Eur J Clin Invest. 2009. Vol. 39, N 7. P. 618–625. doi: 10.1111/j.1365-2362.2009.02153.x

[27] Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med. 2016;36(1):78–80. doi: 10.5144/0256-4947.2016.78

[28] Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus // Ann Saudi Med. 2016. Vol. 36, N 1. P. 78–80. doi: 10.5144/0256-4947.2016.78

[29] Petrakis D, Margină D, Tsarouhas K, et al. Obesity — A risk factor for increased COVID-19 prevalence, severity and lethality (Review). Mol Med Rep. 2020;22(1):9–19. doi: 10.3892/mmr.2020.11127

[30] Petrakis D., Margină D., Tsarouhas K., et al. Obesity — A risk factor for increased COVID-19 prevalence, severity and lethality (Review) // Mol Med Rep. 2020. Vol. 22, N 1. P. 9–19. doi: 10.3892/mmr.2020.11127

[31] Babenko AYu, Laevskaya MYu. Diabetes mellitus and COVID-19. How are they connected? Current strategy of fight. Arterial Hypertension. 2020;26(3):304–311. (In Russ). doi: 10.18705/1607-419X-2020-26-3-304-311

[32] Бабенко А.Ю., Лаевская М.Ю. Сахарный диабет и COVID-19. Как они связаны? Современные стратегии борьбы // Артериальная гипертензия. 2020. Т. 26, № 3. С. 304–311. doi: 10.18705/1607-419X-2020-26-3-304-311

[33] NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072–1088. doi: 10.1016/S0140-6736(18)31992-5

[34] NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4 // Lancet. 2018. Vol. 392, N 10152. P. 1072–1088. doi: 10.1016/S0140-6736(18)31992-5

[35] Najem RN, Halawi A, Tanios B, et al. May measurement month 2019: An analysis of blood pressure screening results from Lebanon. Eur Heart J Suppl. 2021;23(Suppl. B):B92–B94. doi: 10.1093/eurheartj/suab037

[36] Najem R.N., Halawi A., Tanios B., et al. May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon// Eur Heart J Suppl. 2021. Vol. 23, suppl. B. P. B92–B94. doi: 10.1093/eurheartj/suab037

[37] Shishkova VN, Kapustina LA. Problems of the comorbid patient: How to choose the right statin. Effective Pharmacotherapy. 2017;(1):14–23. (In Russ).

[38] Шишкова В.Н., Капустина Л.А. Проблемы коморбидного пациента: как выбрать правильный статин // Эффективная фармакотерапия. 2017. № 1 (17). С. 14–23.

[39] Karetnikova VN, Zvereva TN, Barbarash OL. Current features of management of comorbid patients with hypertension. Medical Alphabet. 2019;2(30):6–11. (In Russ). doi: 10.33667/2078-5631-2019-2-30(405)-6-11

[40] Каретникова В.Н., Зверева Т.Н., Барбараш О.Л. Особенности ведения коморбидного пациента с артериальной гипертензией на современном этапе // Медицинский алфавит. 2019. Т. 2, № 30. С. 6–11. doi: 10.33667/2078-5631-2019-2-30(405)-6-11

[41] Polozova EI, Seskina AA, Puzanova EV, et al. Comorbid conditions in patients with arterial hypertension. Current Problems of Science and Education. 2019;(4):135. (In Russ).

[42] Полозова Э.И., Сеськина А.А., Пузанова Е.В., и др. Коморбидные состояния у больных артериальной гипертензией // Современные проблемы науки и образования. 2019. № 4. С. 135.

[43] Chazova IE, Blinova NV, Nevzorova VA, et al. Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Systemic Hypertension. 2020;17(3):35–41. (In Russ). doi: 10.26442/2075082X.2020.3.200362

[44] Чазова И.Е., Блинова Н.В., Невзорова В.А., и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: артериальная гипертония и COVID-19 // Системные гипертензии. 2020. Т. 17, № 3. C. 35–41. doi: 10.26442/2075082X.2020.3.200362

[45] Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis. Pol Arch Intern Med. 2020;130(4):304–309. doi: 10.20452/pamw.15272

[46] Lippi G., Wong J., Henry B.M. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis // Pol Arch Intern Med. 2020. Vol. 130, N 4. P. 304–309. doi: 10.20452/pamw.15272

[47] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017

[48] Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis // Int J Infect Dis. 2020. Vol. 94. P. 91–95. doi: 10.1016/j.ijid.2020.03.017

[49] Gasmi A, Peana M, Pivina L, et al. Interrelations between COVID-19 and other disorders. Clin Immunol. 2021;224:108651. doi: 10.1016/j.clim.2020.108651

[50] Gasmi A., Peana M., Pivina L., et al. Interrelations between COVID-19 and other disorders // Clin Immunol. 2021. Vol. 224. P. 108651. doi: 10.1016/j.clim.2020.108651

[51] Rodilla E, Saura A, Jiménez I, et al. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med. 2020;9(10):3136. doi: 10.3390/jcm9103136

[52] Rodilla E., Saura A., Jiménez I., et al. Association of Hypertension with all-cause mortality among hospitalized patients with COVID-19 // J Clin Med. 2020. Vol. 9, N 10. P. 3136. doi: 10.3390/jcm9103136

[53] Iaccarino G, Grassi G, Borghi C, et al.; SARS-RAS Investigators. Age and multimorbidity predict death among COVID-19 patients: Results of the SARS-RAS study of the Italian society of hypertension. Hypertension. 2020;76(2):366–372. doi: 10.1161/HYPERTENSIONAHA.120.15324

[54] Iaccarino G., Grassi G., Borghi C., et al.; SARS-RAS Investigators. Age and multimorbidity predict death among COVID-19 patients: Results of the SARS-RAS study of the Italian society of hypertension // Hypertension. 2020. Vol. 76, N 2. P. 366–372. doi: 10.1161/HYPERTENSIONAHA.120.15324

[55] Sun Y, Guan X, Jia L, et al. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. J Clin Hypertens (Greenwich). 2021;23(2):218–231. doi: 10.1111/jch.14146

[56] Sun Y., Guan X., Jia L., et al. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital // J Clin Hypertens (Greenwich). 2021. Vol. 23, N 2. P. 218–231. doi: 10.1111/jch.14146

[57] Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J. 2020;55(6):2001148. doi: 10.1183/13993003.01148-2020

[58] Leiva Sisnieguez C.E., Espeche W.G., Salazar M.R. Arterial hypertension and the risk of severity and mortality of COVID-19 // Eur Respir J. 2020. Vol. 55, N 6. P. 2001148. doi: 10.1183/13993003.01148-2020

[59] Dedov II, Shestakova MV, Mayorov AYu, editors. Standards of specialized diabetes care. 9th ed. Diabetes Mellitus. 2019;22(1S1):1–144. (In Russ). doi: 10.14341/DM221S1

[60] Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. // Сахарный диабет. 2019. Т. 22, № 1S1. С. 1–144. doi: 10.14341/DM221S1

[61] Nikoloski Z, Alqunaibet AM, Alfawaz RA, et al. COVID-19 and non-communicable diseases: Evidence from a systematic literature review. BMC Public Health. 2021;21(1):1068. doi: 10.1186/s12889-021-11116-w

[62] Nikoloski Z., Alqunaibet A.M., Alfawaz R.A., et al. COVID-19 and non-communicable diseases: Evidence from a systematic literature review // BMC Public Health. 2021. Vol. 21, N 1. P. 1068. doi: 10.1186/s12889-021-11116-w

[63] Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. doi: 10.1016/S2213-8587(20)30152-2

[64] Bornstein S.R., Rubino F., Khunti K., et al. Practical recommendations for the management of diabetes in patients with COVID-19 // Lancet Diabetes Endocrinol. 2020. Vol. 8, N 6. P. 546–550. doi: 10.1016/S2213-8587(20)30152-2

[65] Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr. 2020;14(5):1017–1025. doi: 10.1016/j.dsx.2020.06.064

[66] Nandy K., Salunke A., Pathak S.K., et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events // Diabetes Metab Syndr. 2020. Vol. 14, N 5. P. 1017–1025. doi: 10.1016/j.dsx.2020.06.064

[67] Das S, K RA, Birangal SR, et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life Sci. 2020;258:118202. doi: 10.1016/j.lfs.2020.118202

[68] Das S., K R.A., Birangal S.R., et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review // Life Sci. 2020. Vol. 258. P. 118202. doi: 10.1016/j.lfs.2020.118202

[69] Mahluji S, Jalili M, Ostadrahimi A, et al. Nutritional management of diabetes mellitus during the pandemic of COVID-19: a comprehensive narrative review. J Diabetes Metab Disord. 2021;20(1):963–972. doi: 10.1007/s40200-021-00784-5

[70] Mahluji S., Jalili M., Ostadrahimi A., et al. Nutritional management of diabetes mellitus during the pandemic of COVID-19: a comprehensive narrative review // J Diabetes Metab Disord. 2021. Vol. 20, N 1. P. 963–972. doi: 10.1007/s40200-021-00784-5

[71] Demidova TYu, Volkova ЕV, Grickevich ЕYu. Obesity and COVID-19: A fatal link. Infectious Diseases: News, Opinions, Training. 2020;9(Suppl. 3):25–32. (In Russ). doi: 10.33029/2305-3496-2020-9-3S-25-32

[72] Демидова Т.Ю., Волкова Е.В., Грицкевич Е.Ю. Ожирение и COVID-19: фатальная связь // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 3 (приложение). С. 25–32. doi: 10.33029/2305-3496-2020-9-3S-25-32

[73] Maddaloni E, D’Onofrio L, Alessandri F, et al.; CoViDiab Study Group. Cardiometabolic multimorbidity is associated with a worse COVID-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020;19(1):164. doi: 10.1186/s12933-020-01140-2

[74] Maddaloni E., D’Onofrio L., Alessandri F., et al; CoViDiab Study Group. Cardiometabolic multimorbidity is associated with a worse COVID-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II) // Cardiovasc Diabetol. 2020. Vol. 19, N 1. P. 164. doi: 10.1186/s12933-020-01140-2

[75] Salazar MR. Is hypertension without any other comorbidities an independent predictor for COVID-19 severity and mortality? J Clin Hypertens (Greenwich). 2021;23(2):232–234. doi: 10.1111/jch.14144

[76] Salazar M.R. Is hypertension without any other comorbidities an independent predictor for COVID-19 severity and mortality? // J Clin Hypertens (Greenwich). 2021. Vol. 23, N 2. P. 232–234. doi: 10.1111/jch.14144

[77] Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822. doi: 10.1016/S2213-8587(20)30272-2

[78] Barron E., Bakhai C., Kar P., et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study // Lancet Diabetes Endocrinol. 2020. Vol. 8, N 10. P. 813–822. doi: 10.1016/S2213-8587(20)30272-2

[79] Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513–517. doi: 10.1016/j.dsx.2020.04.049

[80] Pal R., Bhadada S.K. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics // Diabetes Metab Syndr. 2020. Vol. 14, N 4. P. 513–517. doi: 10.1016/j.dsx.2020.04.049

[81] Grinevich VB, Gubonina IV, Doshchitsin VL, et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. (In Russ). doi: 10.15829/1728-8800-2020-2630

[82] Гриневич В.Б., Губонина И.В., Дощицин В.Л., и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020 // Кардиоваскулярная терапия и профилактика. 2020. Т. 19, № 4. С. 2630. doi: 10.15829/1728-8800-2020-2630

[83] Mishchenkova TV, Zvenigorodskaya LA. Obesity — A new non-infectious “Epidemic”. Experimental and Clinical Gastroenterology. 2011;(11):9–14. (In Russ).

[84] Мищенкова Т.В., Звенигородская Л.А. Ожирение — новая неинфекционная «Эпидемия» // Экспериментальная и клиническая гастроэнтерология. 2011. № 11. С. 9–14.

[85] Caballero B. Humans against Obesity: Who will win? Adv Nutr. 2019;10(Suppl. 1):S4–S9. doi: 10.1093/advances/nmy055

[86] Caballero B. Humans against Obesity: Who will win? // Adv Nutr. 2019. Vol. 10, Suppl. 1. P. S4–S9. doi: 10.1093/advances/nmy055

[87] Martinchik AN, Laikam KE, Kozyreva NA, et al. The prevalence of obesity in various socio-demographic groups of the population of Russia. Problems of Nutrition. 2021;90(3):67–76. (In Russ). doi: 10.33029/0042-8833-2021-90-3-67-76

[88] Мартинчик А.Н., Лайкам К.Э., Козырева Н.А., и др. Распространение ожирения в различных социально-демографических группах населения России // Вопросы питания. 2021. Т. 90, № 3. С. 67–76. doi: 10.33029/0042-8833-2021-90-3-67-76

[89] Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. doi: 10.1111/obr.13128. Erratum in: Obes Rev. 2021;22(10):e13305.

[90] Popkin B.M., Du S., Green W.D., et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships // Obes Rev. 2020. Vol. 21, N 11. P. e13128. doi: 10.1111/obr.13128. Erratum in: Obes Rev. 2021. Vol. 22, N 10. P. e13305.

[91] Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open. 2020;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270

[92] Suleyman G., Fadel R.A., Malette K.M., et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit // JAMA Netw Open. 2020. Vol. 3, N 6. P. e2012270. doi: 10.1001/jamanetworkopen.2020.12270

[93] Simonnet A, Chetboun M, Poissy J, et al.; LICORN and the Lille COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195–1199. doi: 10.1002/oby.22831. Erratum in: Obesity (Silver Spring). 2020;28(10):1994.

[94] Simonnet A., Chetboun M., Poissy J., et al.; LICORN and the Lille COVID-19 and obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation // Obesity (Silver Spring). 2020. Vol. 28, N 7. P. 1195–1199. doi: 10.1002/oby.22831. Erratum in: Obesity (Silver Spring). 2020. Vol. 28, N 10. P. 1994.

[95] Kalligeros M, Shehadeh F, Mylona EK, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring). 2020;28(7):1200–1204. doi: 10.1002/oby.22859

[96] Kalligeros M., Shehadeh F., Mylona E.K., et al. Association of obesity with disease severity among patients with coronavirus disease 2019 // Obesity (Silver Spring). 2020. Vol. 28, N 7. P. 1200–1204. doi: 10.1002/oby.22859

[97] Muscogiuri G, Pugliese G, Barrea L, et al. Commentary: Obesity: The “Achilles heel” for COVID-19? Metabolism. 2020;108:154251. doi: 10.1016/j.metabol.2020.154251

[98] Muscogiuri G., Pugliese G., Barrea L., et al. Commentary: Obesity: The “Achilles heel” for COVID-19? // Metabolism. 2020. Vol. 108. P. 154251. doi: 10.1016/j.metabol.2020.154251

[99] Sanchis-Gomar F, Lavie CJ, Mehra MR, et al. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc. 2020;95(7):1445–1453. doi: 10.1016/j.mayocp.2020.05.006

[100] Sanchis-Gomar F., Lavie C.J., Mehra M.R., et al. Obesity and outcomes in COVID-19: When an epidemic and pandemic collide // Mayo Clin Proc. 2020. Vol. 95, N 7. P. 1445–1453. doi: 10.1016/j.mayocp.2020.05.006

[101] Vera-Zertuche JM, Mancilla-Galindo J, Tlalpa-Prisco M, et al. Obesity is a strong risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: a national observational study. Epidemiol Infect. 2021;149:e109. doi: 10.1017/S0950268821001023

[102] Vera-Zertuche J.M., Mancilla-Galindo J., Tlalpa-Prisco M., et al. Obesity is a strong risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: a national observational study // Epidemiol Infect. 2021. Vol. 149. P. e109. doi: 10.1017/S0950268821001023

[103] Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196–4200. doi: 10.1210/jcem.82.12.4450

[104] Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo // J Clin Endocrinol Metab. 1997. Vol. 82, N 12. P. 4196–4200. doi: 10.1210/jcem.82.12.4450

[105] Demidova TYu, Volkova EI, Gritskevich EYu. Peculiarities of the COVID-19 course and consequences in overweight and obese patients. Lessons from the current pandemic. Obesity and Metabolism. 2020;17(4):375–384. (In Russ). doi: 10.14341/omet12663.

[106] Демидова Т.Ю., Волкова Е.И., Грицкевич Е.Ю. Особенности течения и последствия COVID-19 у пациентов с избыточным весом и ожирением. Уроки текущей пандемии // Ожирение и метаболизм. 2020. Т. 17, № 4. С. 375–384. doi: 10.14341/omet12663

[107] De Lucena TMC, da Silva Santos AF, de Lima BR, et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14(4):597–600. doi: 10.1016/j.dsx.2020.05.025

[108] De Lucena T.M.C., da Silva Santos A.F., de Lima B.R., et al. Mechanism of inflammatory response in associated comorbidities in COVID-19 // Diabetes Metab Syndr. 2020. Vol. 14, N 4. P. 597–600. doi: 10.1016/j.dsx.2020.05.025

[109] Nasonov EL. Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. Pulmonologiya. 2020;30(5):629–644. (In Russ). doi: 10.18093/0869-0189-2020-30-5-629-644

[110] Насонов Е.Л. Коронавирусная болезнь-2019 (COVID-19): значение ингибиторов IL-6 // Пульмонология. 2020. Т. 30, № 5. С. 629–644. doi: 10.18093/0869-0189-2020-30-5-629-644

[111] Anisenkova AY, Apalko SV, Asaulenko ZP, et al. Major predictive risk factors for а cytokine storm in COVID-19 patients (a retrospective clinical trials). Journal of Clinical Practice. 2021;12(1):5–15. (In Russ). doi: 10.17816/clinpract63552

[112] Анисенкова А.Ю., Апалько С.В., Асауленко З.П., и др. Основные прогностические факторы риска цитокинового шторма у пациентов с COVID-19 (ретроспективное клиническое исследование) // Клиническая практика. 2021. Т. 12, № 1. C. 5–15. doi: 10.17816/clinpract63552

[113] Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. mBio. 2021;12(1):e03647–20. doi: 10.1128/mBio.03647-20

[114] Ng W.H., Tipih T., Makoah N.A., et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis // mBio. 2021. Vol. 12, N 1. P. e03647–20. doi: 10.1128/mBio.03647-20

[115] Cuschieri S, Grech S. At-risk population for COVID-19: Multimorbidity characteristics of a European small Island state. Public Health. 2021;192:33–36. doi: 10.1016/j.puhe.2020.12.012

[116] Cuschieri S., Grech S. At-risk population for COVID-19: Multimorbidity characteristics of a European small Island state // Public Health. 2021. Vol. 192. P. 33–36. doi: 10.1016/j.puhe.2020.12.012

RIGHTS & PERMISSIONS

Eco-Vector